证券代码：000710 证券简称：贝瑞基因 公告编号：2026-003 成都市贝瑞和康基因技术股份有限公司 关于公司董事辞职暨更换第十届董事会审计委员会部分委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、公司董事辞职的情况 成都市贝瑞和康基因技术股份有限公司董事会（以下简称"公司"或"贝瑞基 因"）于近日收到赵辉先生的书面辞职报告，赵辉先生因个人原因申请辞去第十届董 事会董事、审计委员会委员职务，其担任董事及审计委员会委员的原定任期至公司第 十届董事会任期届满之日止。因赵辉先生的辞任会导致审计委员会成员低于法定最低 人数，因此其辞职报告应于独立董事张大可先生正式就任审计委员会委员之日起正式 生效，赵辉先生辞职后不再担任公司及控股子公司其他职务。 截至本公告披露日，赵辉先生未直接持有公司股票，不存在应履行而未履行的公 开承诺，其承诺遵守《中华人民共和国公司法》（以下简称《公司法》）《深圳证券 交易所上市公司自律监管指引第18号——股东及董事、高级管理人员减持股份》以及 《公司章程》《董事、高级管理人员离职管理制度》等相关规定。 特此公告。 成都市 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2026-004 成都市贝瑞和康基因技术股份有限公司 第十届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第二十次会议于 2026 年 3 月 18 日在北京市昌平区生命园路 4 号院 5 号楼 8 层会 议室以现场与通讯会议相结合的方式召开，会议通知已于 2026 年 3 月 16 日以邮 件形式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。 本次董事会会议应出席董事 7 名，实际出席会议董事 7 名，会议由董事长高扬先 生主持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审议通过《关于更换第十届董事会审计委员会部分委员的议案》 表决结果：7 票同意，0 票反对，0 票弃权。 公司董事会基于公司内部治理及规范运作的需要，并根据《公司法》和《公 司章程》《董事会审计委员会工作细则》的有 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].

Core Viewpoint - Berry Genomics (000710.SZ) forecasts a net loss of 170 million to 250 million yuan for the fiscal year 2025, compared to a loss of 192 million yuan in the same period last year [1] Financial Performance - The company's net profit attributable to shareholders is expected to be a loss of 170 million to 250 million yuan, with a non-GAAP net profit loss of 165 million to 245 million yuan, both reflecting a decline from the previous year's loss of 192 million yuan [1] Revenue and Cash Flow - Revenue has declined due to factors such as a decrease in birth rates, although operating cash flow remains stable [1] Asset Management - The company has conducted a comprehensive review and impairment testing of various assets based on the principle of prudence, which has impacted the net profit for the reporting period [1] Research and Development - Berry Genomics has increased its R&D investment and is actively expanding its product lines, leading to enhanced capabilities in third-generation gene sequencing technology, which has also affected the current net profit due to high R&D expenses [1] Strategic Initiatives - The company is focusing on integrating gene testing technology with artificial intelligence algorithms to promote innovation in precision medicine, which has generated some revenue [1] Business Development - The newborn gene screening business is progressing as expected, which is anticipated to have a significant positive impact on the company's business layout in the reproductive health sector [1]

Core Viewpoint - The company, Berry Genomics, anticipates a net loss for 2025, projecting a net profit attributable to shareholders between -250 million to -170 million yuan, compared to -192 million yuan in 2024 [1][2] Financial Performance - The company expects a net loss of 165 million to 245 million yuan after deducting non-recurring items for 2025, with a corresponding loss of 192 million yuan in 2024 [1] - Revenue has declined during the reporting period, although operating cash flow remains stable [1] Asset Management - Berry Genomics has conducted a comprehensive review and impairment testing of its assets based on prudence, which has impacted the current net profit [1] - The company has increased its R&D investment, which has led to higher expenses affecting the current net profit [1] Business Focus - The main business of Berry Genomics includes gene testing services and related equipment, focusing on reproductive health, genetic disease testing, and technology services [1] - The company aims to integrate gene testing technology with artificial intelligence algorithms to drive innovation in precision medicine, which is expected to generate revenue [2] Market Position - The newborn gene screening business is progressing as expected, which is anticipated to positively impact the company's business layout in reproductive health [2] - From 2021 to 2024 and the first three quarters of 2025, the company's net profit, net profit attributable to shareholders, and net profit after deducting non-recurring items have consistently been negative [2] Shareholder Issues - Recently, the controlling shareholder, Gao Yang, faced a default in stock pledge repurchase business, resulting in the forced execution of 3.5352 million shares, accounting for 0.999% of the company's total share capital [2]

Core Viewpoint - Berry Genomics expects a net profit for the fiscal year 2025 to be negative, projected between -250 million to -170 million yuan [1] Group 1: Financial Performance - The company's operating revenue has declined due to factors such as a decrease in birth rates [1] - Operating cash flow remains stable during the reporting period [1] Group 2: Asset Management - The company has conducted a comprehensive review and impairment testing of various assets based on the principle of prudence, leading to cautious provisions for asset impairments [1] - The impairment provisions have had a certain impact on the net profit for the reporting period [1]

Financial Performance - The company expects a net profit in the range of -25,000 to -17,000 thousand yuan for the fiscal year 2025, compared to a net profit of -19,242.85 thousand yuan in the previous year[5]. - The net profit excluding non-recurring gains and losses is projected to be between -24,500 and -16,500 thousand yuan, compared to -19,219.19 thousand yuan in the same period last year[5]. - The basic earnings per share are expected to be between -0.71 and -0.48 yuan, compared to -0.54 yuan in the previous year[5]. - Non-recurring gains and losses are estimated to impact net profit by approximately 5,000 thousand yuan, compared to 240 thousand yuan in the same period last year[4]. - The company has conducted a comprehensive review and impairment testing of various assets, which has also affected the net profit for the reporting period[4]. - Investors are advised to note that the financial data is based on preliminary calculations and the final figures will be disclosed in the 2025 annual report[6]. Revenue and Market Factors - The decline in revenue is attributed to factors such as a decrease in birth rates, while operating cash flow remains stable[4]. - The newborn genetic screening business is progressing as expected, which is anticipated to positively impact the company's business layout in reproductive health[4]. Research and Development - The company has increased its R&D investment, which has impacted the current net profit due to high phase expenditures[4]. - The integration of genetic testing technology with artificial intelligence algorithms is expected to drive innovation in precision medicine and generate revenue[4].

Core Viewpoint - The advancement of national policies related to reproductive health will significantly increase the demand for fertility health testing, positively impacting the core business development of the company [2] Group 1: Company Strategy - The company has been deeply engaged in the reproductive health sector for many years, focusing on a three-tier prevention system that includes pre-pregnancy, prenatal, and newborn care [2] - The company plans to leverage advanced testing technologies, a comprehensive product system, and a broad network of hospital collaborations to seize market opportunities [2] Group 2: Market Impact - The expansion of the fertility health testing market is expected to support efforts in preventing birth defects [2]

Group 1 - The core point of the news is that on January 26, Berry Genomics executed a block trade of 2.7187 million shares at a transaction price of 11.88 yuan, which represents a discount of 10.74% compared to the market closing price of 13.31 yuan [1][2]. Group 2 - The total transaction amount for the block trade was 32.2982 million yuan, accounting for 9.36% of the total trading volume on that day [1][2]. - The buyer of the shares was Guotai Junan Securities Co., Ltd., while the seller was Jianghai Securities Co., Ltd. [2].

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]